User:Mr. Ibrahem/Dabigatran

From Wikipedia, the free encyclopedia

Dabigatran etexilate
INN: Dabigatran etexilate
Clinical data
Trade namesPradaxa, Pradax, Prazaxa, others
Other namesDabigatran etexilate (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa610024
License data
Pregnancy
category
Routes of
administration		By mouth
Legal status
Legal status
Pharmacokinetic data
Bioavailability3–7%[2]
Protein binding35%[2]
Elimination half-life12–17 hours[2]
Identifiers
  • Ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninate
Chemical and physical data
FormulaC34H41N7O5
Molar mass627.734 g·mol−1
3D model (JSmol)
  • CCCCCCOC(=O)N=C(C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N
  • InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44) checkY
  • Key:KSGXQBZTULBEEQ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation.[2][4] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots.[2] It is used as an alternative to warfarin and does not require monitoring by blood tests.[2] It is taken by mouth.[2]

Common side effects include bleeding and gastritis.[2] Other side effects may include bleeding around the spine and allergic reactions such as anaphylaxis.[2] In cases of severe bleeding, it can be reversed with the antidote, idarucizumab.[2] Use is not recommended during pregnancy or breastfeeding.[2] Compared to warfarin it has fewer interactions with other medications.[5] It is a direct thrombin inhibitor.[4]

Dabigatran was approved for medical use in the United States in 2010.[2] It is on the World Health Organization's List of Essential Medicines.[6] A month supply in the United Kingdom costs the NHS about £51 as of 2019.[4] In the United States the wholesale cost of this amount is about US$416.[7] In 2017, it was the 302nd most commonly prescribed medication in the United States, with more than one million prescriptions.[8]

References[edit]

  1. ^ a b "Dabigatran (Pradaxa) Use During Pregnancy". Drugs.com. 27 December 2018. Retrieved 16 May 2020.
  2. ^ a b c d e f g h i j k l "Dabigatran Etexilate Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.
  3. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 8 September 2020.
  4. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 135–137. ISBN 9780857113382.
  5. ^ Kiser, Kathryn (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438.
  6. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  8. ^ "Dabigatran Etexilate Mesylate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Dabigatran&oldid=1054793494"